Résistance aux inhibiteurs des tyrosines kinases dans le cancer du rein
- PMID: 30595154
- DOI: 10.1016/S0007-4551(18)30380-1
Résistance aux inhibiteurs des tyrosines kinases dans le cancer du rein
Abstract
FOCUS ON RESISTANCE TO TYROSINE KINASE INHIBITORS IN RENAL CANCER: The last decade has seen significant advances in understanding the biology and genetics of kidney cancer, some of which have radically changed treatment standards, including the emergence of targeted therapies. TKIs have significantly improved outcome in patients with metastatic disease. Nevertheless, a subset of patients (approximately 25 %) does not show any clinical benefit from targeted therapies. In many cases, patients initially respond to therapy but resistance to targeted agents has been shown to develop after a median of 6-12 months of treatment. Two general models of tumor resistance to anti-angiogenic agents targeting the VEGF pathway have been proposed: an adaptive (evasive) resistance, which occurs after a prolonged application of a drug (providing a period of tumor control), or intrinsic one (preexisting) non-responsiveness despite the presence of an active agent, showing no therapeutic benefit. Intrinsic resistance is related to tumor redundancy of pro-angiogenic pathways. Acquired resistance is associated with activation of alternative pathways either by upregulation of the VEGF pathway or by recruitment of alternative angiogenic factors responsible for tumor revascularization. Because different combinations and sequences of TKI are tested in clinical trials and immunotherapy (alone or in combination) radically alters patient management in its metastatic disease, the current effort aims at identifying resistance processes, evaluating their importance and proposing rational therapeutic approaches in order to obtain an additional clinical benefit. Our article summarizes the different mechanisms of resistance described in the literature.
Keywords: Acquired and intrinsic; Cancer du rein; Drug resistance; Inhibiteurs de tyrosine; Metastatic renal cell; Résistance acquise; Résistance intrinsèque; Tyrosine kinase; adaptative; carcinoma; inhibitors; kinase; métastatique; resistance.
© 2018 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés.
Similar articles
-
Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms.Biochim Biophys Acta. 2014 Jan;1845(1):31-41. doi: 10.1016/j.bbcan.2013.10.001. Epub 2013 Oct 14. Biochim Biophys Acta. 2014. PMID: 24135488 Review.
-
Resistance to angiogenesis inhibitors in renal cell carcinoma.Clin Adv Hematol Oncol. 2011 Feb;9(2):101-10. Clin Adv Hematol Oncol. 2011. PMID: 22173604
-
Cancer du rein métastatique : recommandations et perspectives en 1re ligne.Bull Cancer. 2018 Dec;105 Suppl 3:S235-S241. doi: 10.1016/S0007-4551(18)30378-3. Bull Cancer. 2018. PMID: 30595152 Review. French.
-
Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.Pharmacol Res. 2017 Jun;120:116-132. doi: 10.1016/j.phrs.2017.03.010. Epub 2017 Mar 19. Pharmacol Res. 2017. PMID: 28330784 Review.
-
[Medical treatment of renal cell carcinoma].Prog Urol. 2013 Nov;23(15):1225-37. doi: 10.1016/j.purol.2013.09.011. Epub 2013 Oct 21. Prog Urol. 2013. PMID: 24183081 Review. French.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous